All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-09-28T10:11:57.000Z

How could new immunotherapy modalities in AML change current practice?

By Zoe Brunn, Mark Maitland
Featured
Amir Fathi
Sep 28, 2021
Share:

Bookmark this article

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How could new immunotherapy modalities in acute myeloid leukemia (AML) change current practice?

How could new immunotherapy modalities in AML change current practice?

Fathi begins by outlining the immunotherapeutic gemtuzumab ozogamicin and the multiple treatment settings in which it is approved. He goes on to describe how and why he uses this therapy in his practice. Finally, Fathi discusses further drug targets and the treatments that correspond to them, such as CD3 and Flotetuzumab.

 

More about...
FlotetuzumabGemtuzumab ozogamicinImmune modulatorsSOHO 2021

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new...

Sep 21, 2021
Add bookmark

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer...

Sep 21, 2021
Add bookmark

FLAG-IDA for acute myeloid leukemia

Summary of two abstract presented at ASH 2019 focusing on the FLAG-IDA regimen for the treatment of AML.

Jan 21, 2020
Add bookmark

FLAG-IDA for acute myeloid leukemia

Summary of two abstract presented at ASH 2019 focusing on the FLAG-IDA regimen for the treatment of AML.

Jan 21, 2020

Newsletter

Subscribe to get the best content related to AML delivered to your inbox